1 year return (CAGR)
3194.57%
Active Biotech AB Exchange (ST, SEK)
ACTI.ST
3.83
+0.10 (+2.41%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
151.61%
5 year return (CAGR)
58.10%
10 year return (CAGR)
6.28%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
112.03M
Price/Sales
-
Ent value
78.83M
Price/Book
3.01
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-16.59%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 4.11 |
| Daily high | 4.30 |
| Daily low | 4.10 |
| Daily Volume | 35K |
| All-time high | 103.64 |
| 1y analyst estimate | 25.00 |
| Beta | 1.34 |
| EPS (TTM) | -1.27 |
| Dividend per share | 0.00 |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 7 May 2026 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -96.31% | -1.79% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 18 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -92.38% | -10.67% |
| Avg time to new high | 3722 days | 12 days |
| Max time to new high | 7442 days | 1805 days |
News
Abogen Biosciences ("Abogen" or the "Group"), a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis to advan...
October 2, 2026
Suominen Corporation's stock exchange release on October 1, 2026, at 3:15 p.m. (EEST) Suominen Corporation (hereinafter the “Company”) has transferred without consideration a total of 324,000 of Compa...
October 1, 2026
Investing.com -- Deutsche Bank on Thursday named its top European stock picks for the next 12 months, adding six new names and dropping six from its third-quarter list.
October 1, 2026
Suominen Corporation October 1, 2026, at 3:00 p.m. (EEST) Suominen Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Charle...
October 1, 2026
Actis-backed Rezolv Energy has secured up to €561m ($636.3m) in project financing to advance its 1.3GWp Dama Solar project in Arad County, western Romania, into the construction phase.
October 1, 2026
Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 20...
October 1, 2026
AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 202...
September 30, 2026
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technologi...
September 30, 2026
SCHRAMBERG, GERMANY - September 29, 2026 (NEWMEDIAWIRE) - Shares in Schweizer Electronic AG (ISIN: DE0005156236, WKN: 515623) will be traded on the Scale segment of the Frankfurt Stock Exchange from 3...
September 29, 2026
CAS, a division of the American Chemical Society, today announced a collaboration with Novartis Biomedical Research focused on enhancing reaction data accessibility and supporting AI-enabled research....
September 29, 2026